Menu
Peptide Database
Results
No peptides found
Featured

Use search to browse all 100+ peptides

MGF Igf-1-ec

IGF-1Ec, IGF-1Eb, Mechano-Growth Factor

Quick Stats
Studies 62
Trials 100
Completed OBSERVATIONAL NCT05039879

Life Improving Factors After a Hip Fracture

View on ClinicalTrials.gov Updated Dec 15, 2025

Brief Summary

The primary objective of the proposed research is to investigate the association between protein intake and nutritional status with bone health and physical functioning in older hip fracture patients. In addition, it will be investigated which patient characteristics and modifiable factors can predict mobility, clinical frailty, living situation and mortality. This study will be a 3-month prospective cohort study in adults aged 70 years and older with an acute hip fracture. This study will lead to knowledge about how protein intake and nutritional status in combination with patient characteristics can predict the degree of recovery (bone health and physical functioning) 3 months after the hip fracture. Knowledge on factors related to recovery can contribute to an improved and shorter rehabilitation in the future, which results in a reduction of health care costs.

Detailed Description

Only half of the patients with an acute hip fracture regain their pre-fracture functional level and 24% dies within the following year. Identifying and targeting modifiable risk factors for optimal recovery after a hip fracture is therefore essential. These factors include protein intake and nutritional status, which may affect markers of bone health and physical functioning and thereby influence recovery. Measurements will be performed at baseline (within 5 days after the hip surgery) and after 3 months during an outpatient clinic visit for the evaluation of the hip fracture surgery. A total of 95 older adults (aged 70 years or older) recovering from an acute hip fracture will be recruited from Rijnstate hospital.

Primary Outcomes

Measure: Protein intake
TimeFrame: Baseline
Description: Dietary protein intake will be recorded using a protein screener which gives an indication of protein intake in g/d. Based on the past 4 weeks.
Measure: Protein intake
TimeFrame: Three months
Description: Dietary protein intake will be recorded using a protein screener which gives an indication of protein intake in g/d. Based on the past 4 weeks.
Measure: Nutritional status
TimeFrame: Baseline
Description: Using the Mini Nutritional Assessment Short Form. Subjects will be classified as having a normal nutritional status (12-14 points), having a risk of malnutrition (8-11 points), or being undernourished (0-7 points).
Measure: Nutritional status
TimeFrame: Three months
Description: Using the Mini Nutritional Assessment Short Form. Subjects will be classified as having a normal nutritional status (12-14 points), having a risk of malnutrition (8-11 points), or being undernourished (0-7 points).
Measure: Procollagen type 1 N propeptide
TimeFrame: Baseline
Description: Bone turnover marker, in serum
Measure: Procollagen type 1 N propeptide
TimeFrame: Three months
Description: Bone turnover marker, in serum
Measure: C-terminal telopeptide of type I collagen
TimeFrame: Baseline
Description: Bone turnover marker
Measure: C-terminal telopeptide of type I collagen
TimeFrame: Three months
Description: Bone turnover marker
Measure: Calcaneus quantitative ultrasound parameters
TimeFrame: Baseline
Description: Ultrasound of the calcaneus which gives an indication of the bone density. Device yields the following two parameters: speed of sound (SOS) and broadband ultrasound attenuation (BUA), which can be combined to get the Stiffness Index (SI).
Measure: Calcaneus quantitative ultrasound parameters
TimeFrame: Three months
Description: Ultrasound of the calcaneus which gives an indication of the bone density. Device yields the following two parameters: speed of sound (SOS) and broadband ultrasound attenuation (BUA), which can be combined to get the Stiffness Index (SI).
Measure: Insulin-like growth factor 1
TimeFrame: Baseline
Description: In serum
Measure: Insulin-like growth factor 1
TimeFrame: Three months
Description: In serum
Measure: Parathyroid hormone levels
TimeFrame: Baseline
Description: In serum
Measure: Parathyroid hormone levels
TimeFrame: Three months
Description: In serum
Measure: Handgrip strength
TimeFrame: Baseline
Description: Using the Martin vigorimeter
Measure: Handgrip strength
TimeFrame: Three months
Description: Using the Martin vigorimeter
Measure: Grip work
TimeFrame: Baseline
Description: Using the Martin vigorimeter
Measure: Grip work
TimeFrame: Three months
Description: Using the Martin vigorimeter

Trial Information

NCT ID

NCT05039879

Status

Completed

Study Type

OBSERVATIONAL

Sponsor

Wageningen University

Last Updated

December 15, 2025